zipalertinib Plus Chemotherapy Completes FDA Submission for First-Line NSCLC with EGFR Exon 20 Insertion Mutations

Written by

in

Cullinan Therapeutics has completed and submitted to the FDA an NDA for zipalertinib plus platinum-based chemotherapy for previously untreated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Source:CancerNetwork · Read original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *